Background: One of the major causes of liver disease in the world is hepatitis B virus (HBV) infection. The liver as a homeostatic organ plays a pivotal role in maintaining the relative balance of lipid and lipoprotein metabolism in the body. Aim: The study aimed at determining the impact of chronic hepatitis B (CHB) disease on serum lipids and the effect of the stages of this disease on lipid pattern in infected patients. Methodology: The study involved the selection of 70 CHB patients attending clinic at a Tertiary Hospital in Makurdi, Nigeria. After fulfilling the inclusion criteria, 65 anthropometrically matched apparently healthy individuals were selected as control to the CHB group. CHB is defined in the study as persistent infection evidenced by seropositivity for hepatitis B surface antigen without remission for up to 1-year. Results: There was a significantly reduced (P = 0.001) high-density lipoprotein cholesterol (HDL-C) and raised (P = 0.044) low-density lipoprotein cholesterol (LDL-C) in chronic HBV compared to seronegative controls. There was a significantly lowered HDL-C (P = 0.017), very LDL-C (P = 0.005), and triglyceride (P = 0.034) in asymptomatic CHB compared to the matched controls. There was a significantly lowered total cholesterol (P = 0.019) and HDL-C (P = 0.017) in symptomatic CHB compared to the matched controls. Conclusion: Lowered serum lipids are associated with CHB disease and likely to be mediated altered liver metabolism. However, reasons for the low levels of lipids in this viral disease still remains unclear.
INTRODUCTION
One of the major causes of liver disease in the world is hepatitis B virus (HBV) infection. [1] HBV could cause either acute or chronic viral hepatitis, which may lead to liver cirrhosis or hepatocellular carcinoma subsequently resulting to death. [2] Only few acute HBV infections are symptomatic. [3] Less than ten percent of children and about 50% of adults with acute HBV are reported to have jaundice. [4] Individuals who fail to spontaneously or naturally clear the virus after acute infection become chronic carriers of the viruses. [4] Chronicity to HBV infection has been defined as continuously testing positive to hepatitis B surface antigen (HBsAg) for 6 months or longer. [4, 5] Two billion people in the world are estimated to be infected with HBV, [6] of this number, an estimated 350 million (representing 17.5% of the 2 billion) worldwide are chronically infected with HBV. [5] About 600,000 deaths occur yearly due to the consequences of acute or chronic HBV. [7] The liver as a homeostatic organ plays a pivotal role in maintaining the relative balance of lipid and lipoprotein metabolism in vivo, modulating both endogenous and exogenous cycles of lipid metabolism. It is involved in the sequestration, remodeling (synthesis or recycling), and redistribution of lipid metabolites including
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lipoproteins such as low-density lipoproteins (LDLs), high-density lipoproteins (HDLs), and their corresponding apolipoproteins, triglycerides (TGs), and total plasma cholesterol. [8, 9] Thus, the extracellular circulating levels of these metabolites in plasma depend significantly on the functional integrity of the hepatic tissues. Thus, compromising the functional integrity of the hepatic tissue by hepatitis B (HB) could be linked with dyslipidemia.
It has been well documented that chronic liver dysfunction might interfere with lipid metabolism in vivo and could change plasma lipid and lipoprotein patterns. [10] The previous studies also suggest that chronic HBV infection has an inverse association with all lipids. [11, 12] Pathophysiologically, there are two main stages of chronic HB (CHB) infection-chronic symptomatic (fulminant CHB infection) and chronic asymptomatic stage with their attendant pathological manifestations. However, most studies of dyslipidemia involving CHB infection have not investigated the bearing of these stages on lipid profile of infected hosts. The aim of this study, therefore, was to assess the impact of chronic viral HB on lipid profile and the effect of the stages of this disease on plasma lipid pattern.
METHODOLOGY
Subject selection
The Institutional Ethical clearance was obtained from the Tertiary Hospital in Makurdi, Nigeria. Seventy chronic viral HB patients attending the hospital and 65 apparently healthy individuals who fulfilled the inclusion aged 18-55 years were selected, respectively, as the test group and the control group. Informed consent was sought from the participants by educating them on the nature of the study. A structured questionnaire was administered to the consented patients, who answered the questions and returned same. The inclusion criteria involved patients who continuously tested positive for HBsAg for up to 1-year during their periodic visit to the clinic, apparently healthy individuals with the desired blood pressure (BP), and anthropometric indices. The exclusion criteria comprised subjects with conditions that predisposes to dyslipidemia.
Study design
To obtain host plasma lipoprotein pattern solely based on HBV effect, anthropometric effects on plasma lipids must be eliminated. The study groups were therefore anthropometrically matched for valid comparisons. The lipid profile of chronic hepatitis B virus (CHBV) subjects (n = 70) were compared with anthropometrically matched controls (n = 65). Using a cutoff alanine amino transferase value of greater and <36 U/L, the CHB subjects (n = 70) were subgrouped into symptomatic (n = 14) and asymptomatic (n = 56) CHB, respectively. The plasma lipids of the symptomatic (n = 14) and asymptomatic (n = 56) chronic hepatitis C subjects were statistically compared with that of their anthropometrically matched controls (n = 14 and n = 56, respectively).
Laboratory methods
Four milliliters of fasting venous blood samples were aseptically collected from the selected subjects and processed into serum samples for the determination of HBsAg, T/HDL/LDL cholesterol, and TGs.
The monolisa HBsAg ultra enzyme-linked immunosorbent assay (ELISA) kit, obtained from Bio-Rad Marnes-la-Coquette France, was used for the assay of HBsAg. Determination of HBsAg was based on the ELISA sandwich principle. Immobilized mouse monoclonal anti-HBs antibodies bind HBsAg in sample. The amount of the antigen bound depends on the amount in sample. A second monoclonal antibody, peroxidase labeled is added to the mixture which binds the available epitopes on the HBsAg. The amount of the second monoclonal antibody bound to the HBsAg is proportional to the amount of HBsAg. On addition of an enzyme substrate, a product is formed which react with the chromogen tetramethylbenzidine to yield a colored solution. The intensity of the solution is proportional to the concentration of the HBsAg present in the sample.
The reagent kit for the determination of cholesterol, HDL-C, and TG was obtained from Randox Laboratories Limited, United Kingdom. TC was determined by the cholesterol esterase method. Free cholesterol is liberated from cholesterol esters by cholesterol esterase. The free cholesterol is oxidized by cholesterol oxidase to yield a ketone and hydrogen peroxide. The hydrogen peroxide is converted into water and oxygen, which is immediately used for the oxidation of para aminophenazone in a phenol solution giving rise to a pink colored solution. The intensity of the colored solution is directly proportional to the concentration of cholesterol in the sample. The HDL-C was determined by the cholesterol esterase method after fractional separation from other lipids. The HDL-C reagent is a mixture of cholesterol esterase, cholesterol oxidase, and catalase. These enzymes eliminate chylomicrons, very LDL-cholesterol (VLDL-C), and LDL-C. HDL-C is released into the supernatant mixture of detergent and serum after centrifugation. The HDL-C fraction extracted is measured the cholesterol esterase method used in cholesterol determination. TGs were determined using the lipase method. Lipase hydrolyses TG into hydrogen peroxide, subsequently acted on by peroxidase to produce water and oxygen. The oxygen is immediately used for the oxidation of para aminophenazone which in the presence of phenol yields a pink-colored quinoneimine dye, whose color intensity is directly proportional to the concentration of TG in the serum. LDL-C and VLDL-C were estimated using the Friedewald equation. [13] 
Statistical analysis
The statistical package IBM SPSS version 21 (IBM Armonk, New York, United States) was used in analyzing the data generated. Descriptive statistics were used in determining the means and standard deviations of the parameters measured. The Student's t-test was used in comparing the means of parameters in CHBV and control groups. A two-tailed P < 0.05 was indicative of statistical significance. Table 1 shows the BP, age, body mass index (BMI), fasting TC., HDL-C, LDL-C, VLDL-C and TG in chronic HBV, and seronegative subjects. There was no significant (P > 0.05) difference between the mean systolic BP, diastolic BP, age, BMI of CHB, and controls. There was a significantly reduced (P = 0.001) HDL-C and raised (P = 0.044) LDL-C in chronic HBV compared to seronegative controls. Whereas no significant difference in mean fasting serum TC, VLDL-C, TG was observed between chronic HBV and seronegative subjects. Table 2 shows the BP, anthropometric parameters, lipid profile of asymptomatic CHB, and controls. There was no significant (P > 0.05) difference between the mean systolic BP, diastolic BP, age, BMI of asymptomatic CHB, and controls. There was a significantly lowered HDL-C (P = 0.017), VLDL-C (P = 0.005), and TG (P = 0.034) in asymptomatic CHB compared to the matched controls whereas no significant (P > 0.05) difference in mean fasting serum TC, LDL-C was observed between asymptomatic CHB and matched subjects. Table 3 shows the BP, anthropometric parameters, lipid profile of symptomatic CHB, and controls. There was no significant (P > 0.05) difference between the mean systolic BP, diastolic BP, age, BMI of symptomatic CHB, and controls. There was a significantly lowered TC (P = 0.019) and HDL-C (P = 0.017) in symptomatic CHB compared to the matched controls whereas no significant (P > 0.05) difference in mean fasting serum LDL-C, VLDL-C, and TG was observed between symptomatic CHB and matched subjects.
RESULTS
DISCUSSION
HBV is one of the leading causes of liver disease. The liver is the major organ that metabolizes lipids. Several studies have linked the association of liver diseases irrespective of the etiology with dyslipidemia. Various case-controlled studies reported dyslipidemia in CHB disease, however, with differing lipid profile pattern. Based on liver involvement, CHB disease is classified into asymptomatic and symptomatic CHB disease. Besides the overall CHB patients, our study further determined the lipid profile pattern in asymptomatic and symptomatic CHB groups, to establish a lipid profile pattern dependent and independent of the liver. The CHB groups were extensively matched with age, BMI, and BP controls to eliminate false results which could emanate from the already established causes of the metabolic syndrome.
Our study revealed a statistically low HDL-C in the unsubgrouped, asymptomatic, and symptomatic CHB patients compared to their matched controls. TC was found to be low in all the CHB groups compared to their matched controls. However, the low TC was statistical only in the symptomatic CHB group. This result agrees with the study of Su et al., who reported an association between asymptomatic chronic HBV infection and lower serum levels of TC and HDL-C. [14] Low TC level has also been reported in CHB patients compared to controls by other studies. [12, [15] [16] [17] [18] Hsu et al.
reported a lower HDL-C in CHB patients, [19] while Chung et al. reported a lower HDL-C in CHB men compared to controls. [20] In our study, a statistically low TG level was observed in the asymptomatic CHB subgroup compared with its matched control. No statistical difference was observed in TG levels of ungrouped and symptomatic CHB patients compared with their matched controls. This result is in line with the studies of Choi et al., and Chen et al., who reported that HBsAg positivity was associated with lower prevalence of hypertriglyceridemia. [11, 21] Other studies also reported low TG levels in CHB patients compared to controls. [11, 12, 16, 17, 19, [21] [22] [23] We observed a statistically low VLDL-C in the asymptomatic CHB subgroup compared to its matched controls. The ungrouped and symptomatic CHB patients also revealed low VLDL-C when compared [15, 18] The study reveals a statistically elevated LDL-C level in the ungrouped CHB compared with its matched control. In addition, a nonstatistical elevated LDL-C was observed in the asymptomatic CHB subgroup compared with the matched controls. This agrees with studies by Li et al., and Kwarteng et al., who showed elevated LDL-C in CHB patients compared to controls. [17, 23] Some published studies did not find any difference in the levels of LDL-C in patients with CHB and controls. [14] [15] [16] Nevertheless, other studies reported significantly low LDL-C in CHB patients compared to controls. [12, 15, 18, 19] Most of the studies in literature ascribed dyslipidemia in CHB patients as an outcome of impaired hepatic function. Whether there are nonhepatic causes of yet to be established, lipid profile pattern in CHB disease remains unanswered.
There are four proteins that originate from the HBV genome including polymerase, a surface protein, a core protein, and the HBx protein. Among these proteins, HBx protein has been reported to induce hepatic steatosis and inflammation. [24] The previous reports have demonstrated that HBx proteins induce the expression of lipid synthesis-related genes and inflammation in the liver transgenic mice. [25] [26] [27] The consequence of the interaction of HBx protein with host hepatic metabolic genes is to switch hepatic metabolism from fatty acid synthesis and secretion through lipoproteins to increased hepatic lipid synthesis and storage. [26, 28] Thus, the liver becomes more adipogenic sequestering most of the lipids that diffuse into it, creating a steatotic condition in the infected liver. [29] [30] [31] [32] Data from hepatoma cell cultures suggest that hepatocytes infected with HBV have lower concentrations of apolipoprotein mRNA. [33] Kang et al. reported the specific impairment of hepatic secretion of apolipoprotein B by HBx protein and further ascribed low serum TG to the same viral protein. [34] Thus, hepatic steatosis and impairment in the secretion of TGs and apolipoproteins could in part explain the lowered plasma lipids observed in our study.
Other studies have demonstrated nonhepatic causes of dyslipidemia in CHB patients. Neurath and Strick in their study reported the binding of apolipoprotein H to the HBsAg with subsequent lowering of the plasma apolipoprotein. [35] The prolonged surge in proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, IL-6, and interferon-alpha (IFN-α) has been linked with dyslipidemia in studies following the chronic state of the HBV-infection. [36] [37] [38] [39] Thus, interaction of HBsAg with apolipoprotein H and lipidemic effect of cytokines could have contributed to the observed distortions in the various lipid indices of the HB-infected population. Cytokines such as the TNF-α, IL-1, IL-6, and IFN-α have been reported to increase lipogenesis, decrease clearance of circulating LDLs, and inhibit hepatic lipase activity. [40] [41] [42] This probably accounts for the observed increase in the serum LDL levels among the HBV-infected populations in our study.
CONCLUSION
Lowered serum lipids are associated with CHB disease and likely to be mediated altered liver metabolism. However, reasons for the low levels of lipids in this viral disease still remains unclear. Therefore, the role of HBV in lipid metabolism should be further explored.
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